# A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

> **NCT07188896** · PHASE2 · RECRUITING · sponsor: **Brian Rini** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma (aRCC)
- Metastatic Renal Cell Carcinoma ( mRCC)
- Clear Cell Renal Cell Carcinoma (ccRCC)

## Interventions

- **DRUG:** Fianlimab
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT07188896
- **Lead sponsor:** Brian Rini
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-29
- **Primary completion:** 2029-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188896, "A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07188896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*